ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.

Detalhes bibliográficos
Autor(a) principal: VirgÃnia ClÃudia Carneiro GirÃo
Data de Publicação: 2006
Tipo de documento: Tese
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações da UFC
Texto Completo: http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=57
Resumo: We investigate in this work the role of the central nervous system in the modulation of the inflammatory peripheral pain in the zymosan induced arthritis (AZy) in rats. Cerebrospinal fluid (CSF) and sinovial fluid were collected from animals at different AZy times (1, 3, 6, 12 and 14 hours) in order to determine the nitrite level. Different groups of male, Wistar rats (n=6), 250 to 300g weight, were then submitted to surgery in order to place a cannula in the subarachnoid space, to allow for intrathecal (i.t) insertion of substances. The animals were also submitted to AZy followed by the paw suspension test (PST) that measures articular incapacitation (AI), aiming to analyze hyperalgesia in this experimental model. The pharmacological modulation was achieved by the prophylactic or therapeutic i.t administration of a NO donor (SIN-1), NOS inhibitors (L-NAME, 1400W), a soluble Guanylate cyclase inhibitor (ODQ), a GMPc analogue (8-Bromo-GMPc) and an NMDA receptor antagonist (MK-801). The ODQ was also administered intraarticulary to one group of animals. The results are expressed as mean  s.e.m, followed by ANOVA and the Tukey test, comparing to the groups that received the vehicle. The levels of nitrite in the CSF were smaller at 1 and 3 hours after zymosan injection, as compared with basal levels (P<0.05). The surgical procedure did not alter hyperalgesia. SIN-1 i.t (10 mcg) reduced the AI, while 40mcg increased the AI (P<0.05). L-NAME or 1400W, prophylactic or therapeutic, reduced the AI (P<0.05). ODQ i.t, prophylactic, but not therapeutic, reduced the AI, and also reverted the AI promoted by the 40mcg of SIN-1. Besides, ODQ, intraarticulary, reverted the AI promoted by the 40mcg of SIN-1, administered i.t. MK-801 i.t inhibited the AI, both caused by AZy and by the 40mcg of SIN-1. The results suggest a central endogenous anti-nociceptive role of NO in the acute articular hyperalgesia of the AZy. The NO, depending on the dose and local where it acts, may present an anti-nociceptive or pro-nociceptive effect in the AZy, both due to the activation of GMPc and the excitation of NMDA receptors. We have shown, for the first time, the existence of a peripheral-central activation way modulating the articular hyperalgesia in the AZy acute phase.
id UFC_55f14ff919674efe92d1bbe1445ca9e0
oai_identifier_str oai:www.teses.ufc.br:169
network_acronym_str UFC
network_name_str Biblioteca Digital de Teses e Dissertações da UFC
spelling info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. Nitric oxide (NO) participation in central hyperralgesia modulation in modulation in the zymozan induced artritis (AZy) in rats.2006-03-15Francisco Airton Castro da Rocha23373474353http://lattes.cnpq.br/4916026652021507Geanne Matos de Andrade21911258320http://lattes.cnpq.br/9935129797137635Carlos MaurÃcio de Castro Costa01356810306http://lattes.cnpq.br/9291210203141568 Diana CÃlia Sousa Nunes-Pinheiro15563278387http://lattes.cnpq.br/3376562859305916Maria Josà Pereira Vilar15479110420http://lattes.cnpq.br/426536992247093746447512353http://lattes.cnpq.br/5491102217675347VirgÃnia ClÃudia Carneiro GirÃoUniversidade Federal do CearÃPrograma de PÃs-GraduaÃÃo em FarmacologiaUFCBRArtrite Dor Ãxido NÃtricoArtritis Pain Nitric OxideFARMACOLOGIAWe investigate in this work the role of the central nervous system in the modulation of the inflammatory peripheral pain in the zymosan induced arthritis (AZy) in rats. Cerebrospinal fluid (CSF) and sinovial fluid were collected from animals at different AZy times (1, 3, 6, 12 and 14 hours) in order to determine the nitrite level. Different groups of male, Wistar rats (n=6), 250 to 300g weight, were then submitted to surgery in order to place a cannula in the subarachnoid space, to allow for intrathecal (i.t) insertion of substances. The animals were also submitted to AZy followed by the paw suspension test (PST) that measures articular incapacitation (AI), aiming to analyze hyperalgesia in this experimental model. The pharmacological modulation was achieved by the prophylactic or therapeutic i.t administration of a NO donor (SIN-1), NOS inhibitors (L-NAME, 1400W), a soluble Guanylate cyclase inhibitor (ODQ), a GMPc analogue (8-Bromo-GMPc) and an NMDA receptor antagonist (MK-801). The ODQ was also administered intraarticulary to one group of animals. The results are expressed as mean  s.e.m, followed by ANOVA and the Tukey test, comparing to the groups that received the vehicle. The levels of nitrite in the CSF were smaller at 1 and 3 hours after zymosan injection, as compared with basal levels (P<0.05). The surgical procedure did not alter hyperalgesia. SIN-1 i.t (10 mcg) reduced the AI, while 40mcg increased the AI (P<0.05). L-NAME or 1400W, prophylactic or therapeutic, reduced the AI (P<0.05). ODQ i.t, prophylactic, but not therapeutic, reduced the AI, and also reverted the AI promoted by the 40mcg of SIN-1. Besides, ODQ, intraarticulary, reverted the AI promoted by the 40mcg of SIN-1, administered i.t. MK-801 i.t inhibited the AI, both caused by AZy and by the 40mcg of SIN-1. The results suggest a central endogenous anti-nociceptive role of NO in the acute articular hyperalgesia of the AZy. The NO, depending on the dose and local where it acts, may present an anti-nociceptive or pro-nociceptive effect in the AZy, both due to the activation of GMPc and the excitation of NMDA receptors. We have shown, for the first time, the existence of a peripheral-central activation way modulating the articular hyperalgesia in the AZy acute phase.Nesse trabalho, investigamos a participaÃÃo do sistema nervoso central (SNC) na modulaÃÃo da dor inflamatÃria perifÃrica na artrite induzida por zymosan (AZy) em ratos. Coletou-se o lÃquor (LCR) e lavado articular dos animais em diferentes tempos de artrite (1, 3, 6, 12 e 24 horas) para a determinaÃÃo dos nÃveis de nitrito. Em seguida, diferentes grupos de ratos (n=6) machos, Wistar, pesando entre 250 300g, foram submetidos ao procedimento cirÃrgico para colocaÃÃo de uma cÃnula no espaÃo subaracnÃideo, para permitir a administraÃÃo intratecal (i.t) de substÃncias. Os animais foram tambÃm submetidos à artrite induzida por zymosan (AZy) seguida da realizaÃÃo do teste de suspensÃo da pata (TSP) para permitir a avaliaÃÃo da incapacitaÃÃo articular (IA), refletindo a hiperalgesia no modelo. A modulaÃÃo farmacolÃgica foi realizada atravÃs da administraÃÃo i.t, de forma profilÃtica ou terapÃutica, de um doador de NO (SIN-1), de inibidores de NOS (L-NAME, 1400W), de um inibidor da guanilato ciclase solÃvel (ODQ), de um anÃlogo do GMPc (8-Bromo-GMPc) e de um antagonista dos receptores NMDA (MK-801). Em um grupo, o ODQ foi tambÃm administrado por via i.a. Os resultados foram expressos em mÃdia  e.p.m., seguida de ANOVA e Teste de Tukey, comparando-se aos grupos que receberam o veÃculo. Os nÃveis de nitrito no LCR foram menores à 1 e 3 h apÃs a injeÃÃo do zymosan, em relaÃÃo aos valores basais (P<0,05). O procedimento cirÃrgico nÃo alterou a hiperalgesia. SIN-1 i.t (10mcg) reduziu a IA, mas 40 mcg de SIN-1 aumentaram a IA (P<0,05). L-NAME ou 1400W, de forma profilÃtica ou terapÃutica, reduziram a IA (P<0,05). ODQ i.t, profilÃtico, mas nÃo terapÃutico, reduziu a IA da AZy e tambÃm reverteu a IA promovida por 40mcg de SIN-1. Ainda, ODQ, intra-articular, reverteu a IA promovida por 40mcg de SIN-1, i.t., MK-801 i.t inibiu a IA tanto da AZy quanto de 40mcg de SIN-1. Os resultados sugerem um papel antinociceptivo endÃgeno central do NO na hiperalgesia articular aguda da AZy. O NO, a depender da dose e do local de aÃÃo, pode ter efeito prà ou anti-nociceptivo, por ativaÃÃo de GMPc e excitaÃÃo de receptores NMDA. De forma inÃdita, demonstramos a existÃncia de uma via de ativaÃÃo perifÃrico-central modulando a hiperalgesia articular na fase aguda da AZy.CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel SuperiorConselho Nacional de Desenvolvimento CientÃfico e TecnolÃgicohttp://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=57application/pdfinfo:eu-repo/semantics/openAccessporreponame:Biblioteca Digital de Teses e Dissertações da UFCinstname:Universidade Federal do Cearáinstacron:UFC2019-01-21T11:13:10Zmail@mail.com -
dc.title.pt.fl_str_mv ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.
dc.title.alternative.en.fl_str_mv Nitric oxide (NO) participation in central hyperralgesia modulation in modulation in the zymozan induced artritis (AZy) in rats.
title ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.
spellingShingle ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.
VirgÃnia ClÃudia Carneiro GirÃo
Artrite
Dor
Ãxido NÃtrico
Artritis
Pain
Nitric Oxide
FARMACOLOGIA
title_short ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.
title_full ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.
title_fullStr ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.
title_full_unstemmed ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.
title_sort ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.
author VirgÃnia ClÃudia Carneiro GirÃo
author_facet VirgÃnia ClÃudia Carneiro GirÃo
author_role author
dc.contributor.advisor1.fl_str_mv Francisco Airton Castro da Rocha
dc.contributor.advisor1ID.fl_str_mv 23373474353
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/4916026652021507
dc.contributor.referee1.fl_str_mv Geanne Matos de Andrade
dc.contributor.referee1ID.fl_str_mv 21911258320
dc.contributor.referee1Lattes.fl_str_mv http://lattes.cnpq.br/9935129797137635
dc.contributor.referee2.fl_str_mv Carlos MaurÃcio de Castro Costa
dc.contributor.referee2ID.fl_str_mv 01356810306
dc.contributor.referee2Lattes.fl_str_mv http://lattes.cnpq.br/9291210203141568
dc.contributor.referee3.fl_str_mv Diana CÃlia Sousa Nunes-Pinheiro
dc.contributor.referee3ID.fl_str_mv 15563278387
dc.contributor.referee3Lattes.fl_str_mv http://lattes.cnpq.br/3376562859305916
dc.contributor.referee4.fl_str_mv Maria Josà Pereira Vilar
dc.contributor.referee4ID.fl_str_mv 15479110420
dc.contributor.referee4Lattes.fl_str_mv http://lattes.cnpq.br/4265369922470937
dc.contributor.authorID.fl_str_mv 46447512353
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/5491102217675347
dc.contributor.author.fl_str_mv VirgÃnia ClÃudia Carneiro GirÃo
contributor_str_mv Francisco Airton Castro da Rocha
Geanne Matos de Andrade
Carlos MaurÃcio de Castro Costa
Diana CÃlia Sousa Nunes-Pinheiro
Maria Josà Pereira Vilar
dc.subject.por.fl_str_mv Artrite
Dor
Ãxido NÃtrico
topic Artrite
Dor
Ãxido NÃtrico
Artritis
Pain
Nitric Oxide
FARMACOLOGIA
dc.subject.eng.fl_str_mv Artritis
Pain
Nitric Oxide
dc.subject.cnpq.fl_str_mv FARMACOLOGIA
dc.description.sponsorship.fl_txt_mv CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior
Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico
dc.description.abstract.por.fl_txt_mv We investigate in this work the role of the central nervous system in the modulation of the inflammatory peripheral pain in the zymosan induced arthritis (AZy) in rats. Cerebrospinal fluid (CSF) and sinovial fluid were collected from animals at different AZy times (1, 3, 6, 12 and 14 hours) in order to determine the nitrite level. Different groups of male, Wistar rats (n=6), 250 to 300g weight, were then submitted to surgery in order to place a cannula in the subarachnoid space, to allow for intrathecal (i.t) insertion of substances. The animals were also submitted to AZy followed by the paw suspension test (PST) that measures articular incapacitation (AI), aiming to analyze hyperalgesia in this experimental model. The pharmacological modulation was achieved by the prophylactic or therapeutic i.t administration of a NO donor (SIN-1), NOS inhibitors (L-NAME, 1400W), a soluble Guanylate cyclase inhibitor (ODQ), a GMPc analogue (8-Bromo-GMPc) and an NMDA receptor antagonist (MK-801). The ODQ was also administered intraarticulary to one group of animals. The results are expressed as mean  s.e.m, followed by ANOVA and the Tukey test, comparing to the groups that received the vehicle. The levels of nitrite in the CSF were smaller at 1 and 3 hours after zymosan injection, as compared with basal levels (P<0.05). The surgical procedure did not alter hyperalgesia. SIN-1 i.t (10 mcg) reduced the AI, while 40mcg increased the AI (P<0.05). L-NAME or 1400W, prophylactic or therapeutic, reduced the AI (P<0.05). ODQ i.t, prophylactic, but not therapeutic, reduced the AI, and also reverted the AI promoted by the 40mcg of SIN-1. Besides, ODQ, intraarticulary, reverted the AI promoted by the 40mcg of SIN-1, administered i.t. MK-801 i.t inhibited the AI, both caused by AZy and by the 40mcg of SIN-1. The results suggest a central endogenous anti-nociceptive role of NO in the acute articular hyperalgesia of the AZy. The NO, depending on the dose and local where it acts, may present an anti-nociceptive or pro-nociceptive effect in the AZy, both due to the activation of GMPc and the excitation of NMDA receptors. We have shown, for the first time, the existence of a peripheral-central activation way modulating the articular hyperalgesia in the AZy acute phase.
Nesse trabalho, investigamos a participaÃÃo do sistema nervoso central (SNC) na modulaÃÃo da dor inflamatÃria perifÃrica na artrite induzida por zymosan (AZy) em ratos. Coletou-se o lÃquor (LCR) e lavado articular dos animais em diferentes tempos de artrite (1, 3, 6, 12 e 24 horas) para a determinaÃÃo dos nÃveis de nitrito. Em seguida, diferentes grupos de ratos (n=6) machos, Wistar, pesando entre 250 300g, foram submetidos ao procedimento cirÃrgico para colocaÃÃo de uma cÃnula no espaÃo subaracnÃideo, para permitir a administraÃÃo intratecal (i.t) de substÃncias. Os animais foram tambÃm submetidos à artrite induzida por zymosan (AZy) seguida da realizaÃÃo do teste de suspensÃo da pata (TSP) para permitir a avaliaÃÃo da incapacitaÃÃo articular (IA), refletindo a hiperalgesia no modelo. A modulaÃÃo farmacolÃgica foi realizada atravÃs da administraÃÃo i.t, de forma profilÃtica ou terapÃutica, de um doador de NO (SIN-1), de inibidores de NOS (L-NAME, 1400W), de um inibidor da guanilato ciclase solÃvel (ODQ), de um anÃlogo do GMPc (8-Bromo-GMPc) e de um antagonista dos receptores NMDA (MK-801). Em um grupo, o ODQ foi tambÃm administrado por via i.a. Os resultados foram expressos em mÃdia  e.p.m., seguida de ANOVA e Teste de Tukey, comparando-se aos grupos que receberam o veÃculo. Os nÃveis de nitrito no LCR foram menores à 1 e 3 h apÃs a injeÃÃo do zymosan, em relaÃÃo aos valores basais (P<0,05). O procedimento cirÃrgico nÃo alterou a hiperalgesia. SIN-1 i.t (10mcg) reduziu a IA, mas 40 mcg de SIN-1 aumentaram a IA (P<0,05). L-NAME ou 1400W, de forma profilÃtica ou terapÃutica, reduziram a IA (P<0,05). ODQ i.t, profilÃtico, mas nÃo terapÃutico, reduziu a IA da AZy e tambÃm reverteu a IA promovida por 40mcg de SIN-1. Ainda, ODQ, intra-articular, reverteu a IA promovida por 40mcg de SIN-1, i.t., MK-801 i.t inibiu a IA tanto da AZy quanto de 40mcg de SIN-1. Os resultados sugerem um papel antinociceptivo endÃgeno central do NO na hiperalgesia articular aguda da AZy. O NO, a depender da dose e do local de aÃÃo, pode ter efeito prà ou anti-nociceptivo, por ativaÃÃo de GMPc e excitaÃÃo de receptores NMDA. De forma inÃdita, demonstramos a existÃncia de uma via de ativaÃÃo perifÃrico-central modulando a hiperalgesia articular na fase aguda da AZy.
description We investigate in this work the role of the central nervous system in the modulation of the inflammatory peripheral pain in the zymosan induced arthritis (AZy) in rats. Cerebrospinal fluid (CSF) and sinovial fluid were collected from animals at different AZy times (1, 3, 6, 12 and 14 hours) in order to determine the nitrite level. Different groups of male, Wistar rats (n=6), 250 to 300g weight, were then submitted to surgery in order to place a cannula in the subarachnoid space, to allow for intrathecal (i.t) insertion of substances. The animals were also submitted to AZy followed by the paw suspension test (PST) that measures articular incapacitation (AI), aiming to analyze hyperalgesia in this experimental model. The pharmacological modulation was achieved by the prophylactic or therapeutic i.t administration of a NO donor (SIN-1), NOS inhibitors (L-NAME, 1400W), a soluble Guanylate cyclase inhibitor (ODQ), a GMPc analogue (8-Bromo-GMPc) and an NMDA receptor antagonist (MK-801). The ODQ was also administered intraarticulary to one group of animals. The results are expressed as mean  s.e.m, followed by ANOVA and the Tukey test, comparing to the groups that received the vehicle. The levels of nitrite in the CSF were smaller at 1 and 3 hours after zymosan injection, as compared with basal levels (P<0.05). The surgical procedure did not alter hyperalgesia. SIN-1 i.t (10 mcg) reduced the AI, while 40mcg increased the AI (P<0.05). L-NAME or 1400W, prophylactic or therapeutic, reduced the AI (P<0.05). ODQ i.t, prophylactic, but not therapeutic, reduced the AI, and also reverted the AI promoted by the 40mcg of SIN-1. Besides, ODQ, intraarticulary, reverted the AI promoted by the 40mcg of SIN-1, administered i.t. MK-801 i.t inhibited the AI, both caused by AZy and by the 40mcg of SIN-1. The results suggest a central endogenous anti-nociceptive role of NO in the acute articular hyperalgesia of the AZy. The NO, depending on the dose and local where it acts, may present an anti-nociceptive or pro-nociceptive effect in the AZy, both due to the activation of GMPc and the excitation of NMDA receptors. We have shown, for the first time, the existence of a peripheral-central activation way modulating the articular hyperalgesia in the AZy acute phase.
publishDate 2006
dc.date.issued.fl_str_mv 2006-03-15
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
status_str publishedVersion
format doctoralThesis
dc.identifier.uri.fl_str_mv http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=57
url http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=57
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal do CearÃ
dc.publisher.program.fl_str_mv Programa de PÃs-GraduaÃÃo em Farmacologia
dc.publisher.initials.fl_str_mv UFC
dc.publisher.country.fl_str_mv BR
publisher.none.fl_str_mv Universidade Federal do CearÃ
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da UFC
instname:Universidade Federal do Ceará
instacron:UFC
reponame_str Biblioteca Digital de Teses e Dissertações da UFC
collection Biblioteca Digital de Teses e Dissertações da UFC
instname_str Universidade Federal do Ceará
instacron_str UFC
institution UFC
repository.name.fl_str_mv -
repository.mail.fl_str_mv mail@mail.com
_version_ 1643295113209708544